Nurix Therapeutics (NRIX) Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Revenue for 8 consecutive years, with $9.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Revenue fell 79.47% year-over-year to $9.0 million; the TTM figure through May 2026 stood at $36.8 million (down 58.4% YoY), while the FY2025 annual figure was $84.0 million, up 53.95% from the prior year.
• Revenue improved to $9.0 million in Q2 2026 per NRIX's latest filing, from $6.3 million in the prior quarter.
• Across five years, Revenue topped out at $44.1 million in Q2 2025 and bottomed at $6.3 million in Q1 2026.
• Historically, Revenue has averaged $15.0 million across 5 years, with a median of $12.6 million in 2023.
• Annual changes were most pronounced in 2025 — Revenue surged 264.34% — and 2026, when it tumbled 79.47%.
• Nurix Therapeutics' Revenue stood at $6.8 million in 2022, then surged by 123.49% to $15.2 million in 2023, then fell by 12.37% to $13.3 million in 2024, then grew by 2.21% to $13.6 million in 2025, then slumped by 33.39% to $9.0 million in 2026.
• Business Quant data shows NRIX's Revenue at $9.0 million in Q2 2026, $6.3 million in Q1 2026, and $13.6 million in Q4 2025.